KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$118.18
+0.76%Sep 1, 2026, 11:00 UTC
Kymera Therapeutics announced presentations on KT-621, a first-in-class oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses.
Source:Aug 5, 2026, 17:06 UTC
Kymera Therapeutics completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule.
Source:Aug 5, 2026, 00:00 UTC
Kymera Therapeutics reported Q2 2026 financial results with collaboration revenue of $65.0 million, a net loss of $61.2 million, and diluted EPS of -$0.62.
Jun 25, 2026, 13:58 UTC
Kymera Therapeutics completed enrollment in its Phase 2b BROADEN2 trial for KT-621, an experimental eczema therapy, nearly six months ahead of schedule.
Jun 10, 2026, 15:51 UTC
Kymera Therapeutics starts patient dosing in a phase I study of KT-485 for hidradenitis suppurativa, triggering a $20 million milestone payment from Sanofi.
Source:Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.